



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	Bucks and Berks AF Stroke Prevention Programme
<b>Project partners</b>	Oxford Academic Health Science Network Bayer plc
<b>Project summary</b>	<p>This was a primary care quality improvement project aimed at improving the management of atrial fibrillation patients across Buckinghamshire and Berkshire.</p> <p>The project involved a pharmacist led data review of patients with known AF at GP Practices across Buckinghamshire and Berkshire.</p> <p>Patients were identified who were at high risk of stroke and either not anticoagulated, or not adequately anticoagulated.</p> <p>Implementation of a consultation review and provision of optimal treatment for those patients formed part of a quality improvement project, to enable improvements in outcomes.</p> <p>A Quality Improvement Support Team was set up to facilitate upskilling each practice to ensure implementation of patient reviews, and leave a QI expertise legacy within the practice, which can be applied to different patient groups.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b>Benefits to Patients :</b></p> <ul style="list-style-type: none"><li>• Prompt assessment of their anticoagulation needs</li><li>• Rapid access to the most appropriate treatments</li><li>• Reduction in the risk of stroke by optimising treatment</li><li>• Better awareness of their condition</li></ul> <p><b>Benefits to NHS:</b></p> <ul style="list-style-type: none"><li>• Improved outcomes in AF by being able to fully implement NICE guidelines</li><li>• Potential reduction in stroke rates and the demands on resources associated with that</li><li>• Upskilling of primary care in both the management of AF and quality improvement techniques</li><li>• Opportunity to test transferability of a successful AHSN project into a new health economy</li></ul>

	<b>Benefits to Bayer:</b> <ul style="list-style-type: none"><li>• Increasing the number of patients suitable for anticoagulation in line with NICE guidance including NOACs* which may include rivaroxaban</li><li>• Ability to develop a partnership with an AHSN</li><li>• Opportunity to test transferability of a successful AHSN collaboration into a new health economy</li></ul>
<b>Start date</b>	January 2017

\* = Novel oral anticoagulants

Date of Reapproval: August 2020

Job bag number: PP-UN-CAR-GB-0018